These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

84 related articles for article (PubMed ID: 14719493)

  • 1. Provinces create centralized system for assessing new drugs.
    Hillson G
    Can HIV AIDS Policy Law Rev; 2002 Dec; 7(2-3):31. PubMed ID: 14719493
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inter-provincial variation in government drug formularies.
    Grégoire JP; MacNeil P; Skilton K; Moisan J; Menon D; Jacobs P; McKenzie E; Ferguson B
    Can J Public Health; 2001; 92(4):307-12. PubMed ID: 11962119
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Do provincial drug benefit initiatives create an effective policy lab? The evidence from Canada.
    Pomey MP; Morgan S; Church J; Forest PG; Lavis JN; McIntosh T; Smith N; Petrela J; Martin E; Dobson S
    J Health Polit Policy Law; 2010 Oct; 35(5):705-42. PubMed ID: 21123668
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A dog's breakfast: prescription drug coverage varies widely across Canada.
    Anis AH; Guh D; Wang Xh
    Med Care; 2001 Apr; 39(4):315-26. PubMed ID: 11329519
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A cost-effectiveness approach to drug subsidy and pricing in Australia.
    Birkett DJ; Mitchell AS; McManus P
    Health Aff (Millwood); 2001; 20(3):104-14. PubMed ID: 11585158
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Regulators deny access to experimental hepatitis C drug.
    Hillson G
    Can HIV AIDS Policy Law Rev; 2002 Dec; 7(2-3):31-2. PubMed ID: 14719494
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Better Prescription: Advice for a National Strategy on Pharmaceutical Policy in Canada.
    Morgan SG; Gagnon MA; Mintzes B; Lexchin J
    Healthc Policy; 2016 Aug; 12(1):18-36. PubMed ID: 27585023
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Health Canada proposes new regulatory regime for drugs.
    Kondro W
    CMAJ; 2007 Apr; 176(9):1261-2. PubMed ID: 17452653
    [No Abstract]   [Full Text] [Related]  

  • 9. FDA's proposed regulations to expand access to investigational drugs for treatment use: the status quo in the guise of reform.
    Rossen BR
    Food Drug Law J; 2009; 64(1):183-223. PubMed ID: 19998746
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [How AMOG limits the supply of diabetes drugs].
    Oberhofer E
    MMW Fortschr Med; 2015 Aug; 157(14):24. PubMed ID: 26289868
    [No Abstract]   [Full Text] [Related]  

  • 11. Access to drugs for cancer: Does where you live matter?
    Menon D; Stafinski T; Stuart G
    Can J Public Health; 2005; 96(6):454-8. PubMed ID: 16350873
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bill 102: deal or no deal for big pharma.
    Rasky H
    Health Law Can; 2007 May; 27(4):73-84. PubMed ID: 17580795
    [No Abstract]   [Full Text] [Related]  

  • 13. Comparison of oncology drug approval between Health Canada and the US Food and Drug Administration.
    Ezeife DA; Truong TH; Heng DY; Bourque S; Welch SA; Tang PA
    Cancer; 2015 May; 121(10):1688-93. PubMed ID: 25604014
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmaceutical policies in Canada: another example of federal-provincial discord.
    Anis AH
    CMAJ; 2000 Feb; 162(4):523-6. PubMed ID: 10701389
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Regulators in access to anticancer drugs in Canada].
    Côté A; Keating B; Parent M; Simard G
    Sante Publique; 2015; 27(4):515-27. PubMed ID: 26751926
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Need for an improved submission process for listing drugs for reimbursement in Canadian provinces.
    West R; Borden EK; Collet JP; Rawson NS; Tonks RS
    Can J Clin Pharmacol; 2003; 10(4):207-10. PubMed ID: 14712327
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Vascular specialists in a campaign against positive list. Threat of deficient care for 4.5 million vascular patients].
    Krankenpfl J; 2003; 41(4-6):120. PubMed ID: 12929329
    [No Abstract]   [Full Text] [Related]  

  • 18. "New approach" as Health Canada seeks conditional licences for drugs, new pediatric office.
    Eggertson L
    CMAJ; 2005 Mar; 172(7):864. PubMed ID: 15743911
    [No Abstract]   [Full Text] [Related]  

  • 19. [Limited prescribing freedom by federal cost regulation?].
    Lasek R
    Z Arztl Fortbild Qualitatssich; 1997 Nov; 91(7):633-5. PubMed ID: 9527458
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Providing health economic data to managed care.
    Navarro RP
    Manag Care Interface; 1998 Sep; 11(9):62-3, 66. PubMed ID: 10187588
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.